Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  McMahan, Zsuzsanna H ^a   Bingham, Clifton O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AZATHIOPRINE; BELIMUMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TETANUS TOXOID; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; USTEKINUMAB; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE; IMMUNOSUPPRESSIVE AGENT;

CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DRUG RESPONSE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION RISK; NONHUMAN; REVIEW; RHEUMATIC DISEASE; SYSTEMATIC REVIEW; VACCINATION; ANIMAL; DRUG EFFECTS; GENETICS; IMMUNOGENETICS; IMMUNOLOGY; IMMUNOMODULATION; RHEUMATIC DISEASES; TREATMENT OUTCOME;

ANIMALS; HUMANS; IMMUNOGENETIC PHENOMENA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; RHEUMATIC DISEASES; TREATMENT OUTCOME; VACCINES;

EID: 84924286319     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0506-0     Document Type: Review

References (55)

1. Curtis JR, Arora T, Narongroeknawin P, Taylor A, Bingham CO 3rd, Cush J, Saag KG, Safford M, Delzell E: The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther 2010, 12:R144.
2. Duchet-Niedziolka P, Launay O, Coutsinos Z, Ajana F, Arlet P, Barrou B, Beytout J, Bouchaud O, Brouqui P, Buzyn A, Chidiac C, Couderc LJ, Debord T, Dellamonica P, Dhote R, Duboust A, Durrbach A, Fain O, Fior R, Godeau B, Goujard C, Hachulla E, Marchou B, Mariette X, May T, Meyer O, Milpied N, Morlat P, Pouchot J, Tattevin P, et al: Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. Vaccine 2009, 27:1523-1529.
3. Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, Noroski LM, Revell PA, Hanson IC, Paul ME, Rosenblatt HM, Abramson SL: Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010, 362:314-319.
4. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC): Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30. quiz CE2-4.
5. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR: Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012, 308:43-49.
6. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR: Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013, 309:887-895.
7. Pileggi GS, de Souza CB, Ferriani VP: Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken) 2010, 62:1034-1039.
8. Borte S, Liebert UG, Borte M, Sack U: Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009, 48:144-148.
9. Scheinberg M, Guedes-Barbosa LS, Mangueira C, Rosseto EA, Mota L, Oliveira AC, Lima RA: Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken) 2010, 62:896-898.
10. Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, Bonilla FA, Conley ME, Cunningham-Rundles C, Filipovich AH, Fuleihan R, Gelfand EW, Hernandez-Trujillo V, Holland SM, Hong R, Lederman HM, Malech HL, Miles S, Notarangelo LD, Ochs HD, Orange JS, Puck JM, Routes JM, Stiehm ER, Sullivan K, Torgerson T, Winkelstein J, Medical Advisory Committee of the Immune Deficiency Foundation: Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 2014, 133:961-966.
11. Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM: Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 2011, 204:1475-1482.
12. Bridges CB, Woods L, Coyne-Beasley T, ACIP Adult Immunization Work Group, Centers for Disease Control and Prevention (CDC): Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older - United States, 2013. MMWR Surveill Summ 2013, 62:9-19.
13. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B: Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013, 31:3594-3602.
14. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, Rubins JB: Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002, 34:147-153.
15. Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, Sylvestre MP: Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012, 71:1128-1133.
16. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC, CORRONA Investigators: Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010, 69:380-386.
17. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P: Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007, 46:608-611.
18. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A: Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74.
19. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M: Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
20. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L: Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol 2011, 30:1555-1561.
21. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L, Saxne T, Geborek P: Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011, 63:3723-3732.
22. Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M: Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-204427. [Epub ahead of print]
23. Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, Smits GP, van Gageldonk PG, Berbers GA, Wulffraat NM: Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013, 309:2449-2456.
24. Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ Jr: Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997, 175:871-875.
25. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA, H1N1 Study Group: Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011, 63:1486-1496.
26. Mok CC, Ho LY, Fong LS, To CH: Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013, 72:659-664.
27. Trollmo C, Gudmundsson S, Feltelius N, Rogberg S, Smedegard G, Klareskog L: Sulphasalazine inhibits human antigen-specific immune responses in vivo. Ann Rheum Dis 2007, 66:481-485.
28. Kanerud L, Engstrom GN, Tarkowski A: Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis. Ann Rheum Dis 1995, 54:256-262.
29. Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, van der Klis FR, Sanders EA, Vermeer-De Bondt PE, Hoes AW, van der Net JJ, Engels C, Kuis W, Prakken BJ, Van Tol MJ, Wulffraat NM: Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 2007, 56:639-646.
30. Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, Franca IL, Carvalho JF, Sampaio-Barros PD, Goncalves CR, Borba EF, Timenetsky Mdo C, Precioso AR, Duarte A, Bonfa E, Laurindo IM: Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011, 70:2144-2147.
31. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, Kallenberg CG, Bijl M: Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006, 65:913-918.
32. Keshtkar-Jahromi M, Argani H, Rahnavardi M, Mirchi E, Atabak S, Tara SA, Gachkar L, Noori-Froothghe A, Mokhtari-Azad T: Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am J Nephrol 2008, 28:654-660.
33. Holvast A, Stegeman CA, Benne CA, Huckriede A, Wilschut JC, Palache AM, Kallenberg CG, Bijl M: Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009, 68:873-878.
34. Sanchez-Fructuoso AI, Prats D, Naranjo P, Fernandez-Perez C, Gonzalez MJ, Mariano A, Gonzalez J, Figueredo MA, Martin JM, Paniagua V, Fereres J, Gomez de la Concha E, Barrientos A: Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000, 69:436-439.
35. Struijk GH, Minnee RC, Koch SD, Zwinderman AH, van Donselaar-van der Pant KA, Idu MM, ten Berge IJ, Bemelman FJ: Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010, 78:934-940.
36. Mercado U, Acosta H, Diaz-Molina R: Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis. J Rheumatol 2009, 36:1549-1550.
37. Palestine AG, Roberge F, Charous BL, Lane HC, Fauci AS, Nussenblatt RB: The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans. J Clin Immunol 1985, 5:115-121.
38. Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W: Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 1986, 42:376-379.
39. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P: Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111.
40. Ferreira I, Isenberg D: Vaccines and biologics. Ann Rheum Dis 2014, 73:1446-1454.
41. Hua C, Barnetche T, Combe B, Morel J: Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014, 66:1016-1026.
42. Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Morner A, Geborek P: Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014, 16:R2.
43. Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW: Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002, 103:13-21.
44. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M: Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007, 9:R38.
45. Schiff M, Kaell A, Tay L, Vratsanos G, Baart K: Pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF Therapy treated with abatacept in the ARRIVE Trial. Ann Rheum Dis 2007, 66:437.
46. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243-1252.
47. Alten R, Bingham CO, Cohen S, Calabrese L, Curtis JR, Blick A, Fay J, Kelly S, Luo A, Wong D, Genovese MA: Antibody response to pneumococcal and influenza vaccineation in patients with RA receiving subcutaneous abatacept. Ann Rheum Dis 2013, 72:579. Abstract SAT0001.
48. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O: Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008, 67:937-941.
49. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, Sarbagil-Maman H, Paran D, Caspi D, Elkayam O: The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011, 29:1643-1648.
50. Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzova D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS, BLISS-76 Study Group: Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012, 39:1632-1640.
51. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K: Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012, 71:2006-2010.
52. Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M: Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-204427.
53. Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P: Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol 2013, 12:1122-1129.
54. Winthrop K, Racewicz A, Lee E, Wilkinson B, Zwillich S, Soma K, Rottinghaus S, Kawabata T, Riese R, Wood S, Bradley J, Bingham CO 3rd: Evaluation of influenza and pneumococcal vaccine responses in patients with rheumatoid arthritis receiving tofacitinib. Arthritis Rheum 2013, 65:Abstract 1284.
55. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Muller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.